Consensus DaVita Inc.

Equities

DVA

US23918K1088

Healthcare Facilities & Services

Delayed Nyse Other stock markets 15:47:35 2026-03-06 EST			5-day change	1st Jan Change
150.94 ^USD	+0.67%		-3.48%	+32.79%

03-02	DaVita Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 11:50 AM
02-13	Three hurt working on Exxon Beaumont, Texas small CDU, sources say	RE

Evolution of the Average Target: DaVita Inc.

Evolution of the Target Price: DaVita Inc.

Changes in Analyst Recommendations: DaVita Inc.

089fe8d1a2c.6kZxsTNyY_2J5cp6e8VjeXoboEQ29F047cBphqY4nwc.vRQh4FYXCsjMsagZPIs2VDlBzQhgsysIpositOFR-HfTAgn3XBQWpbiQ-g~a52460290c8faa37ec0b47476ea3468b

Analysts' recommendations: DaVita Inc.

02-05	Truist Raises Price Target on DaVita to $158 From $128, Keeps Hold Rating	MT
02-05	Analyst recommendations: Corteva, Snap, Alphabet, Eli Lilly, PayPal, Qualcomm…
02-04	TD Cowen Adjusts DaVita Price Target to $144 From $133, Maintains Hold Rating	MT
02-04	UBS Adjusts Price Target on DaVita to $190 From $186, Maintains Buy Rating	MT
02-03	Barclays Adjusts Price Target on DaVita to $158 From $143	MT
01-05	Truist Adjusts Price Target on DaVita to $128 From $140, Maintains Hold Rating	MT
11-03	TD Cowen Adjusts Price Target on DaVita to $133 From $154	MT
25-10-30	Barclays Adjusts Price Target on DaVita to $143 From $149	MT
25-10-30	Deutsche Bank Adjusts Price Target on DaVita to $126 From $137	MT
25-10-08	Barclays Adjusts Price Target on DaVita to $149 From $160	MT
25-08-08	Truist Adjusts Price Target on DaVita to $148 From $164, Maintains Hold Rating	MT
25-08-07	TD Cowen Adjusts DaVita Price Target to $154 From $157, Maintains Hold Rating	MT
25-08-06	Barclays Adjusts DaVita Price Target to $160 From $169	MT
25-08-06	Deutsche Bank Adjusts DaVita Price Target to $137 From $165, Maintains Hold Rating	MT
25-06-18	Bernstein Adjusts Price Target on DaVita to $150 From $184, Maintains Market Perform Rating	MT
25-05-19	Truist Securities Adjusts Price Target on DaVita to $164 From $170, Maintains Hold Rating	MT
25-05-19	TD Cowen Adjusts Price Target on DaVita to $157 From $165, Maintains Hold Rating	MT
25-02-18	TD Cowen Adjusts Price Target on DaVita to $165 From $150, Keeps Hold Rating	MT
25-02-14	Barclays Adjusts Price Target on DaVita to $169 From $164	MT
25-01-28	Bernstein Adjusts Price Target on DaVita to $184 From $161, Maintains Market Perform Rating	MT
24-11-06	Truist Securities Cuts Price Target on DaVita to $170 From $175, Maintains Hold Rating	MT
24-10-31	UBS Adjusts Price Target on DaVita to $186 From $175, Maintains Buy Rating	MT
24-10-30	Deutsche Bank Adjusts Price Target on DaVita to $165 From $145	MT
24-10-30	Barclays Adjusts Price Target on DaVita to $164 From $150	MT
24-10-07	Truist Securities Adjusts Price Target on DaVita to $175 From $165, Maintains Hold Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	DAVITA INC.					+1.18%
	HCA HEALTHCARE, INC.					+1.32%
	CVS HEALTH CORPORATION					+22.49%
	FRESENIUS SE & CO. KGAA					+20.32%
	LABCORP HOLDINGS INC.					+11.48%
	QUEST DIAGNOSTICS INCORPORATED					+7.12%
	DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY					+20.91%
	TENET HEALTHCARE CORPORATION					+6.46%
	REDE D'OR SÃO LUIZ S.A.					+35.81%
	FRESENIUS MEDICAL CARE AG					+13.51%
	Average					+14.06%
	Weighted average by Cap.					+12.73%